BMB-101 Heads for Registrational Trials Following Positive Phase 2 Data in Absence Seizures, Developmental Encephalopathies | NeurologyLive - Clinical Neurology News and Neurology Expert Insights Bright Mind Biosciences reveals promising results for BMB-101 in treating drug-resistant seizures, paving the way for future clinical trials.

🧠⚡ BMB-101 advances toward registrational trials after positive phase 2 data in drug-resistant absence seizures & developmental epileptic encephalopathies.

Read more on what’s next: www.neurologylive.com/view/bmb-101...
#Epilepsy #ClinicalTrials #NeuroPharma #RareDisease #DrugDevelopment #Seizures

🧠💥 Did you know #Depression may be coded in your #Immune system?😲🔥Our paper shows how #Inflammation+ #Kynurenine 🧬shape the #Brain ! @mdpiopenaccess.bsky.social #DrugDiscovery #MedChem #Oncology #Neuropharma
📖Read more👉 www.mdpi.com/1424-8247/18...

🧠💥 Did you know #Depression may be coded in your #Immune system?😲🔥Our paper shows how #Inflammation+ #Kynurenine 🧬shape the #Brain ! @MDPIOpenAccess @Pharmaceut_MDPI #DrugDiscovery #MedChem #Oncology #Neuropharma
📖Read more👉 www.mdpi.com/1424-8247/18...

😱 It’s not just #Serotonin 🎯— #Kynurenine metabolites🧬hijack #Synapses !⚡, driving #Despair😔+ #Anxiety 😵‍💫 @mdpiopenaccess.bsky.social #DrugDiscovery #MedChem #Oncology #Neuropharma
See how🧩in our study
www.mdpi.com/1424-8247/18...

🌙➡️⚡ #Orexins: once “ #Sleep #Peptides,” now unveiled as global controllers of #Behavior, #Metabolism & #Emotion! This Hot Paper Award maps their #Evolution + #Drugs! 💊🧬 @mdpiopenaccess.bsky.social #Neuropharma #HotPaper www.mdpi.com/2227-9059/12...

🧠💥 Did you know #Depression may be coded in your #Immune system?😲🔥Our paper shows how #Inflammation+ #Kynurenine 🧬shape the #Brain ! @mdpiopenaccess.bsky.social #DrugDiscovery #MedChem #Oncology #Neuropharma
📖 Read more 👉 www.mdpi.com/1424-8247/18...

#pharmacology05
#Anticholinergics #vs. #Cholinergics: #Key #Differences at a #iprkashmishra Glance #MedStudents #NursingSchool #Acetylcholine #Anticholinergics #Cholinergics #NeuroPharma #MedEd #MedicalNotes #PharmaMadeEasy

🤔🧪Tiny #Quinoline tweaks→💊⚙️breakthrough #Therapies?🌐 #AI-driven halogenation+esterification=🚀 #Bioavailability&🎯 multitarget action!🔬 @mdpiopenaccess.bsky.social #DrugDiscovery #MedChem #Oncology #Neuropharma
📖 www.mdpi.com/1424-8247/18...

Could tweaking #KYNA unlock safer #Schizophrenia & #Parkinson’s treatments?🤔🧠 SZR-73 preserves motor skills🏃‍♂️👍&shows therapeutic promise💥🔬 @mdpiopenaccess.bsky.social #Neuropharma #KYNA #DrugDiscovery
Read & share! www.mdpi.com/2073-4409/14...

🤔🧪Tiny #Quinoline tweaks→💊⚙️breakthrough #Therapies?🌐 #AI-driven halogenation+esterification=🚀 #Bioavailability&🎯 multitarget action!🔬 @MDPIOpenAccess @Pharmaceut_MDPI #DrugDiscovery #MedChem #Oncology #Neuropharma
📖 www.mdpi.com/1424-8247/18...

🤔🧪🔬💊⚙️🌐What if tiny #Tweaks to $Quinoline scaffolds unlocked breakthrough #Therapies? #AI-driven #Halogenation & #Esterification boost #Bioavailability & #Multitarget action! @mdpiopenaccess.bsky.social #DrugDiscovery #Oncology #Neuropharma
Dive in—read & share! 📖🔁 www.mdpi.com/1424-8247/18...

🤔🧪🔬💊⚙️🌐What if tiny #Tweaks to $Quinoline scaffolds unlocked breakthrough #Therapies? #AI-driven #Halogenation & #Esterification boost #Bioavailability & #Multitarget action! @mdpiopenaccess.bsky.social #DrugDiscovery #Oncology #Neuropharma
Dive in—read & share! 📖🔁 www.mdpi.com/1424-8247/18...

Resveratrol and Its Metabolite as Potential Allosteric Regulators of Monoamine Oxidase A Activity in the Brain and Liver Under Chronic Predator Stress Background: Resveratrol has been shown to modulate stress-related anxiety by reducing brain monoamine oxidase A (MAO-A) activity. However, the molecular mechanism underlying this neurochemical effect remains unknown. In this study, we employed in silico approaches to investigate the binding affinity of resveratrol and its predominant blood metabolite, resveratrol glucuronide, to specific sites on MAO-A. Methods: For the in silico analysis, we employed molecular docking and molecular dynamics simulations. Within the liver–brain axis, we investigated the role of hepatic MAO-A in the development of anxiety. The activity of whole-brain MAO-A was compared with its activity in specific brain regions, including the amygdala, hippocampus, and prefrontal cortex. Results: Our findings suggest the presence of an allosteric site on the enzyme that accommodates these compounds. Furthermore, in vivo experiments demonstrated that high-dose resveratrol suppresses MAO activity not only in the brain but also in the liver of stress-exposed rats. The in vivo results are interpreted in the context of an allosteric site on MAO-A in both the brain and liver, which may mediate the interaction with resveratrol and its metabolite. Conclusions: The primary outcomes of the study include the identification of the role of hepatic MAO-A in the development of anxiety-like behavior, as well as the determination of resveratrol dose ranges at which it functions as an allosteric modulator of MAO-A activity.

💻🕹️🌊🎯 #Docking+100 ns #Dynamics=🎮meets 🌊! #Resveratrol🍇+glucuronide buddy snuggled into a hidden MAO-A pocket (not the usual spot 👀)
Plot twist unlocked! 🔓✨ @mdpiopenaccess.bsky.social #MolecularDocking #Neuropharma doi.org/10.3390/biom...

Psychotropic Drugs Market Size, Trends, Growth Report 2034 Psychotropic Drugs Market Size to reach USD 29.30 Billion at 3.50% CAGR by 2034, by driving industry size, share, top company analysis, segments research, trends and forecast report 2025 to 2032.

🧠💊 Shaping mental wellness, one prescription at a time. The psychotropic drug market is vital for emotional balance. 🧘‍♂️
#MentalHealthMatters #NeuroPharma #PsychotropicDrugs #MindHealth

www.marketresearchfuture.com/reports/psyc...

💻🕹️🌊🎯 #Docking+100 ns #Dynamics=🎮meets 🌊! #Resveratrol🍇+glucuronide buddy snuggled into a hidden MAO-A pocket (not the usual spot 👀)
Plot twist unlocked! 🔓✨ @mdpiopenaccess.bsky.social #MolecularDocking #Neuropharma doi.org/10.3390/biom...

Mercado de esquizofrenia definido para atingir US $ 13.41 bilhões, com um CAGR saudável de 5.49% até as previsões de 2032 – iCrowdNewswire Portuguese

🧠 Schizophrenia treatment market to hit $13.41 Billion by 2032
📈 CAGR projected at 5.49%
🔗 Read More
#PortugalHealth #NeuroPharma #SchizophreniaAwareness #HealthcareGrowth

www.icrowdpt.com/2025/05/19/m...

💻🕹️🌊🎯 #Docking+100 ns #Dynamics=🎮meets 🌊! #Resveratrol🍇+glucuronide buddy snuggled into a hidden MAO-A pocket (not the usual spot 👀)
Plot twist unlocked! 🔓✨ @mdpiopenaccess.bsky.social #MolecularDocking #Neuropharma doi.org/10.3390/biom...